Novel Alpha-(N-Sulfonamido)Acetamide Compound as an Inhibitor of Beta Amyloid Peptide Production
申请人:Starrett, JR. John E.
公开号:US20090111858A1
公开(公告)日:2009-04-30
The present invention provides a novel alpha-(N-sulfonamido)acetamide compound, its pharmaceutical composition, processes thereof and a method for the treatment of Alzheimer's disease and other conditions associated with β-amyloid peptide.
NOVEL ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUNDS INCORPORATING DEUTERIUM AS INHIBITORS OF BETA AMYLOID PEPTIDE PRODUCTION
申请人:Starrett, JR. John E.
公开号:US20100240719A1
公开(公告)日:2010-09-23
The present disclosure provides novel deuterated alpha-(N-sulfonamido)acetamide compounds, their pharmaceutical composition, processes thereof and a method for the treatment of Alzheimer's disease, head trauma, traumatic brain injury, and/or dementia pugilistica and/or other conditions associated with β-amyloid peptide.
[EN] NOVEL COELENTERAZINE SUBSTRATES AND METHODS OF USE<br/>[FR] NOUVEAUX SUBSTRATS DE COELENTÉRAZINE ET PROCÉDÉS D'UTILISATION
申请人:PROMEGA CORP
公开号:WO2012061529A1
公开(公告)日:2012-05-10
An isolated polynucleotide encoding a modified luciferase polypeptide and novel coelenterazine- based substrates. The OgLuc variant polypeptide has at least 60% amino acid sequence identity to SEQ ID NO: 1 and at least one amino acid substitution at a position corresponding to an amino acid in SEQ ID NO: 1. The OgLuc variant polypeptide has at least one of enhanced luminescence, enhanced signal stability, and enhanced protein stability relative to the corresponding polypeptide of the wild-type Oplophorus luciferase.
一个编码修改后的荧光酶多肽和新型荧光素基底的孤立的多聚核苷酸。OgLuc变体多肽至少具有与SEQ ID NO: 1的氨基酸序列相同性的60%,并且至少在一个位置上具有与SEQ ID NO: 1中的氨基酸对应的氨基酸替换。相对于野生型Oplophorus荧光酶的相应多肽,OgLuc变体多肽至少具有增强的荧光、增强的信号稳定性和增强的蛋白稳定性中的至少一种。
NOVEL ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUND AS AN INHIBITOR OF BETA AMYLOID PEPTIDE PRODUCTION
申请人:Starrett, JR. John E.
公开号:US20090227642A1
公开(公告)日:2009-09-10
The present invention provides a method for the treatment of head trauma, traumatic brain injury, and/or dementia pugilistica comprising administering a therapeutically effective amount of (2R)-2-[[(4-chlorophenyl)sulfonyl][[2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl]amino]-5,5,5-trifluoropentanamide.
Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
申请人:Bristol-Myers Squibb Company
公开号:US08084477B2
公开(公告)日:2011-12-27
The present invention provides a novel alpha-(N-sulfonamido)acetamide compound, its pharmaceutical composition, processes thereof and a method for the treatment of Alzheimer's disease and other conditions associated with β-amyloid peptide.